[1]杨俊龙,张 利,肖 洁,等.2012~2021年四川成都某医院临床患者血型意外抗体筛查结果与疾病类型分析[J].现代检验医学杂志,2024,39(01):152-157.[doi:10.3969/j.issn.1671-7414.2024.01.028]
　YANG Junlong,ZHANG Li,XIAO Jie,et al.Analysis of Blood Type Unexpected Antibody Screening Results and Disease Types of Clinical Patients from A Hospital in Chengdu, Sichuan Province from 2012 to 2021[J].Journal of Modern Laboratory Medicine,2024,39(01):152-157.[doi:10.3969/j.issn.1671-7414.2024.01.028]
点击复制

2012~2021年四川成都某医院临床患者血型意外抗体筛查结果与疾病类型分析()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年01期
页码:
152-157
栏目:
检验与临床
出版日期:
2024-01-15

文章信息/Info

Title:
Analysis of Blood Type Unexpected Antibody Screening Results and Disease Types of Clinical Patients from A Hospital in Chengdu, Sichuan Province from 2012 to 2021
文章编号:
1671-7414（2024）01-152-06
作者:
杨俊龙1; 张 利2; 肖 洁3; 黎 欢2; 杨 鑫2; 彭 涛2
（1. 西安国际医学中心医院输血科，西安 710100；2. 西部战区总医院输血科，成都 610083；3. 四川省妇幼保健院/ 成都医学院附属妇女儿童医院输血科，成都 610045）
Author(s):
YANG Junlong1;  ZHANG Li2;  XIAO Jie3;  LI Huan2;  YANG Xin2;  PENG Tao2
（1.Department of Blood Transfusion, Xi’an International Medical Center Hospital, Xi’an 710100, China; 2. Department of Blood Transfusion, the General Hospital of Western Theater Command, Chengdu 610083, China; 3. Department of Blood Transfusion, Sichuan Provincial Maternal and Child Health Hospital/Women and Children Hospital Affiliated to Chengdu Medical College, Chengdu 610045, China）
关键词:
血型; 意外抗体; 抗体筛查; 抗体鉴定; 输血
分类号:
R457.1
DOI:
10.3969/j.issn.1671-7414.2024.01.028
文献标志码:
A
摘要:
目的　对某院住院患者血型意外抗体与疾病特征进行分析，为优化精准输血方案和提高临床输血安全提供参考。方法　收集2012 年1 月～ 2021 年12 月西部战区总医院患者意外抗体筛查和鉴定资料，患者年龄、性别、输血史、妊娠史和疾病诊断，分析意外抗体阳性率、构成比及疾病特征。结果　患者意外抗体筛查阳性率0.55%（1 736/315456），女性高于男性（0.69% vs 0.44%，χ2=90.107，P<0.05），有输血史或（和）妊娠史患者高于无输血史或（和）妊娠史者（75.69% vs 22.81%，χ2=971.098，P<0.05），40 ～ 80 岁患者占72.93%（1 266/1 736）。意外抗体阳性患者主要为消化系统疾病、血液及造血器官免疫疾病、肿瘤、泌尿生殖系统疾病、循环系统疾病、肌肉骨骼系统和结缔组织病，占80.41%（1 396/1 736）。91.88%（1 595/1 736）抗筛阳性患者做了抗体鉴定，意外抗体以Rh 血型系统41.57%（663/1595），Lewis 血型系统11.22%（179/1 595）和MNS 血型系统6.90%（110/1 595）为主，抗体特异性以抗-E[32.41%（517/1595）]、抗-Lea[10.47%（167/1 595）] 和抗-M[6.08%（97/1 595）] 为主，其他抗体[35.8%（571/1 595）] 以未检出特异性抗体为主。结论　患者血型意外抗体筛查结果与疾病类型分析对输血安全有重要意义，输血科应针对长期输血患者、女性、有妊娠史或输血史患者进行多抗原（RhCcDEe，Lea，M）匹配的精准输血，降低意外抗体发生率，提高临床输血安全。
Abstract:
Objective　To analyze blood type unexpected antibody and disease characteristics of inpatients in a hospital, and provide a reference for optimizing precise transfusion schemes and improving clinical transfusion safety. Methods　The data of unexpected antibody screening and identification in the General Hospital of Western Theater Command from January 2012 to December 2021 were collected, while information on these patient age, gender, blood transfusion history, pregnancy history and disease diagnosis were also collected. The positive rate, composition ratio and disease characteristics of unexpected antibodies were analyzed. Results　The positive rate of unexpected antibody screening was 0.55% (1 736/315 456), in which females were higher than males (0.69% vs 0.44%, χ2=90.107, P<0.05), patients with a history of blood transfusion or (and) pregnancy were higher than those without a history of blood transfusion or (and) pregnancy (75.69% vs 22.81%, χ2=971.098, P<0.05), and patients aged 40 ～ 80 accounted for 72.93% (1 266/1 736). Patients diseases with unexpected antibody positive accounted for 80.41% (1 396/1 736), mainly including digestive system diseases, immune diseases of blood and hematopoietic organs, tumors, urogenital system diseases, circulatory system diseases, musculoskeletal system and connective tissue diseases. Moreover, 91.88% (1 595/1 736) of the patients with anti-screening positive underwent antibody identification, in which the majority of unexpected antibodies were Rh blood group system [41.57% (663/1 595)], Lewis blood group system [11.22% (179/1 595)], and MNS blood group system [6.90% (110/1 595)]. Antibody specificity was mainly characterized by anti-E [32.41% (517/1 595)], anti-Lea [10.47% (167/1 595)], and anti-M 6.08% (97/1 595). Other antibodies [35.8% (571/1 595)] were mainly no-detected specific antibodies. Conclusion　The screening results of blood type unexpected antibodies and disease type analysis are of great significance for transfusion safety. Blood transfusion department should carry out precise blood transfusion matching with multiple antigens (RhCcDEe, Lea, M) for long-term transfusion patients, women, and patients with pregnancy or blood transfusion history, so as to reduce the incidence of unexpected antibodies and improve transfusion safety.

参考文献/References:

[1] 中华人民共和国国家卫生健康委员会, WS/T 203-2020: 输血医学术语[S]. 北京: 中国标准出版社, 2020. National Health Commission of the People’s Republic of China. WS/T203-2020: Terminology for transfusion medicine[S]. Beijing: China Standard Press, 2020.
[2] 许亚莉, 吴继博, 徐华, 等. 多中心联合筛查红细胞血型不规则抗体的大数据分析[J]. 中国输血杂志, 2018, 31(8)：823-825. XU Yali, WU Jibo, XU Hua, et al. Big data analysis of multi-center screening for irregular antibodies of erythrocyte blood group[J]. Chinese Journal of Blood Transfusion, 2018, 31(8): 823-825.
[3] WALDIS S J, UTER S, KAVITSKY D, et al. Rh alloimmunization in chronically transfused patients with thalassemia receiving RhD, C, E, and K matched transfusions [J]. Blood Advances, 2021, 5(3): 737-744.
[4] 汪德清. 输血技术操作规程：输血科部分[M]. 北京: 人民卫生出版社, 2016:37-53. WANG Deqing. Operating procedures for blood transfusion technology: blood transfusion department parts[M]. Beijing: People’s Medical Publishing House, 2016:37-53.
[5] MOINUDDIN I, FLETCHER C, MILLWARD P. Prevalence and specificity of clinically significant red cell alloantibodies in pregnant women - a study from a tertiary care hospital in Southeast Michigan[J]. Journal of Blood Medicine, 2019, 10: 283-289.
[6] FACCO G, BENNARDELLO F, FIORIN F, et al. A nationwide survey of clinical use of blood in Italy[J].Blood Transfusion, 2021, 19(5): 384-395.
[7] CHRIS-OLAIYA A, KAPOOR A, RICCI K S, et al. Therapeutic plasma exchange in liver failure[J]. World Journal of Hepatology, 2021, 13(8): 904-915.
[8] 杨俊龙, 甘新宇, 张利, 等. 骨科患者手术用血分析和术前最大红细胞备血量方案建立[J]. 中国输血杂志, 2021, 34(9)：982-986. YANG Junlong, GAN Xinyu, ZHANG Li, et al. Analysis of orthopedic surgical blood transfusion and study on maximum surgical blood order schedule[J].Chinese Journal of Blood Transfusion, 2021, 34(9): 982-986.
[9] 赵桐茂. Rh 基因型匹配输血研究进展[J]. 精准医学杂志, 2019, 34(4)：283-286, 301. ZHAO Tongmao. The research progress of Rh genotype matching transfusion[J]. Journal of Precision Medicine, 2019, 34(4): 283-286, 301.
[10] 桂嵘, 张志昇, 王勇军. 输血相容性检测及疑难病例分析[M]. 北京: 人民卫生出版社,2018:24-42. GUI Rong, ZHANG Zhisheng, WANG Yongjun. Blood transfusion compatibility detection and unusual dufficult cases[M]. Beijing: People’s Medical Publishing House, 2018:24-42.
[11] REE I M C, BESUDEN C F J, WINTJENS V E H J, et al. Exchange transfusions in severe Rh-mediated alloimmune haemolytic disease of the foetus and newborn: a 20-year overview on the incidence, associated risks and outcome[J]. Vox Sanguinis, 2021, 116(9): 990-997.
[12] 侯金友, 李君, 卢焱坤, 等. 预防不规则抗体漏检的实验技术研究[J]. 现代检验医学杂志, 2016, 31(2)：103-104. HOU Jinyou, LI Jun, LU Yankun, et al. Study on the experimental technique for preventing irregular antibody missing detection[J]. Journal of Modern Laboratory Medicine, 2016, 31(2): 103-104.
[15] LI Wangjia, L? Fajin, TAN Yiwen, et al. Benign and malignant pulmonary part-solid nodules: differentiation via thin-section computed tomography[J]. Quantitative Imaging in Medicine and Surgery, 2022, 12(1): 699-710.
[16] ZAHARUDIN N, JAILAINI M F M, ABEED N N N, et al. Prevalence and clinical characteristics of malignant lung nodules in tuberculosis endemic area in a single tertiary centre[J]. BMC Pulmonary Medicine, 2022, 22(1): 328.
[17] KANWAL M, DING Xiaoji, CAO Yi. Familial risk for lung cancer[J]. Oncology Letters, 2017, 13(2): 535-542.
[18] ANG L, CHAN C P Y, YAU W P, et al. Association between family history of lung cancer and lung cancer risk: a systematic review and meta-analysis [J]. Lung Cancer, 2020, 148: 129-137.
[19] LARICI A R, FARCHIONE A, FRANCHI P, et al. Lung nodules:size still matters[J]. European Respiratory Review, 2017, 26(146): 170025.
[20] NOORELDEEN R, BACH H. Current and future development in lung cancer diagnosis[J]. International Journal of Molecular Sciences, 2021, 22(16): 8661.
[21] 王旋, 崔立春, 党升强. 非小细胞肺癌放化疗联合靶向治疗对血清肿瘤标志物、免疫功能及Cyclin D3水平影响的相关研究[J]. 现代检验医学杂志, 2021, 36(4): 25-30. WANG Xuan, CUI Lichun, DANG Shengqiang. Effects of radiotherapy and chemotherapy combined with targeted therapy on serum tumor markers, immune function and CyclinD3 level in non-small cell lung cancer[J]. Journal of Modern Laboratory Medicine, 2021, 36(4): 25-30.
[22] 李辉, 汪春新, 秦明明, 等. 肺癌患者血清7 项肿瘤标志物联合检测在病理分型及临床分期中的应用价值研究[J]. 现代检验医学杂志, 2021, 36(4): 5-9, 121. LI Hui, WANG Chunxin, QIN Mingming, et al. Study on the application value of combined detection of 7 tumor markers in serum of patients with lung cancer in pathological classification and clinical staging[J].Journal of Modern Laboratory Medicine, 2021, 36(4): 5-9, 121.
[23] 彭瑛, 邓正华, 温先勇. 国内13 种血清肿瘤标志物对肺癌诊断价值的Meta分析[J]. 现代检验医学杂志, 2016, 31(1): 96-100. PENG Ying, DENG Zhenghua, WEN Xianyong. Diagnostic value of thirteen types of serum tumor markers for lung cancer in China: a meta-analysis[J].Journal of Modern Laboratory Medicine, 2016, 31(1): 96-100.
[24] 中华医学会肿瘤学分会, 中华医学会杂志社. 中华医学会肺癌临床诊疗指南(2022 版)[J]. 中华医学杂志, 2022, 102(23): 1706-1740. Oncology Society of Chinese Medical Association, Chinese medical association Publishing House. Chinese medical association guideline for clinical diagnosis and treatment of lung cancer(2022 edition)[J]. National Medical Journal of China, 2022, 102(23): 1706-1740.

相似文献/References:

[1]洪　毅,王　华.20例非ABO-HDFN血型血清学分析及临床干预结果比较[J].现代检验医学杂志,2021,36(06):120.[doi:10.3969/j.issn.1671-7414.2021.06.025]
　HONG Yi,WANG Hua.Comparison of Serological Analysis and Clinical Intervention Results of 20 Non-ABO-HDFN Serum Types[J].Journal of Modern Laboratory Medicine,2021,36(01):120.[doi:10.3969/j.issn.1671-7414.2021.06.025]

备注/Memo

备注/Memo:
基金项目： 四川省科技计划项目(NO.2019YFS0273)：基于不同医疗救治能力的精准输血多中心研究；成都医学院校基金2020 年自然科学重点项目(NO.CYZZD20-05) ：四川地区汉族孕妇发生RhE 抗原同种免疫风险与HLA-ORB1 基因多态性的相关性研究。
作者简介：杨俊龙(1989-)，男，本科，主管技师，研究方向：临床输血医学，E-mail:534372079@qq.com。
更新日期/Last Update: 2024-01-15